Brokerages Set aTyr Pharma, Inc. (NASDAQ:ATYR) Target Price at $23.25

aTyr Pharma, Inc. (NASDAQ:ATYR) has received a consensus recommendation of “Hold” from the eight research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $23.25.

A number of analysts recently commented on ATYR shares. Wells Fargo & Company reiterated an “equal weight” rating on shares of aTyr Pharma in a research report on Monday, September 15th. Leerink Partnrs lowered shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 15th. Leerink Partners reissued a “market perform” rating on shares of aTyr Pharma in a research note on Monday, September 15th. Cantor Fitzgerald lowered shares of aTyr Pharma from an “overweight” rating to a “neutral” rating in a report on Monday, September 15th. Finally, Jones Trading lowered shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Profund Advisors LLC acquired a new position in aTyr Pharma in the 3rd quarter worth $27,000. California State Teachers Retirement System bought a new stake in shares of aTyr Pharma in the second quarter valued at about $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of aTyr Pharma during the second quarter worth about $45,000. Legal & General Group Plc bought a new position in shares of aTyr Pharma during the second quarter worth about $49,000. Finally, Prudential Financial Inc. bought a new position in shares of aTyr Pharma during the second quarter worth about $63,000. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Price Performance

ATYR stock opened at $0.71 on Friday. The company has a 50 day moving average price of $0.75 and a 200 day moving average price of $2.64. aTyr Pharma has a fifty-two week low of $0.64 and a fifty-two week high of $7.29. The stock has a market capitalization of $69.84 million, a PE ratio of -0.86 and a beta of 0.60.

aTyr Pharma (NASDAQ:ATYR) last released its earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.06). The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.91 million. As a group, equities analysts expect that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.